Multiple Myeloma in Relapse Completed Phase 1 / 2 Trials for Bortezomib (DB00188)

IndicationStatusPhase
DBCOND0036092 (Multiple Myeloma in Relapse)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00401011Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma PatientsTreatment
NCT01394354Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)Treatment